Tolterodine tartrate
| Status | Commercial |
| Development phase | |
| Therapeutic cat. | Erectile |
| Polymorphic form | Crystalline Form I |
| CAS No. | 124937-52-6 |
| Reference Product | |
| Injectable Form | |
| EU DMF readiness |  |
| CEP | |
| CHINESE DMF | |
| JAPANESE DMF | |
| KOREAN DMF | |
| CANADIAN DMF | |
| CADIFA | |
| US DMF readiness | |
| OEB No. | |
| Samples |
Drug description
Tolterodine is used in adults to treat overactive bladder with symptoms of urinary frequency, urgency, and incontinence (urine leakage).
Polpharma API
Disclaimer
Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subject to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement. It is within the buyer’s responsibility and liability to check the patent situation of the product in the import market(s).
